These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34966045)

  • 1. Cutaneous Plasmacytosis and Idiopathic Multicentric Castleman Disease: A Spectrum of Disease?
    Drissi M; Dunlap R; Clayton L; Raess PW; Mengden Koon S; White K
    Am J Dermatopathol; 2022 Apr; 44(4):294-296. PubMed ID: 34966045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab.
    Aita T; Hamaguchi S; Shimotani Y; Nakamoto Y
    BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33148595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
    Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
    Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous and systemic plasmacytosis in an Asian male born in the North American continent: a controversial entity potentially related to multicentric Castleman disease.
    Shadel BN; Frater JL; Gapp JD; Hurley MY
    J Cutan Pathol; 2010 Jun; 37(6):697-702. PubMed ID: 19614735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease.
    Nishikori A; Nishimura MF; Nishimura Y; Otsuka F; Maehama K; Ohsawa K; Momose S; Nakamura N; Sato Y
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis.
    González García A; Fernández-Martín J; Robles Marhuenda Á
    Rheumatology (Oxford); 2023 Apr; 62(4):1426-1435. PubMed ID: 35997567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
    Belyaeva E; Rubenstein A; Pierson SK; Dalldorf D; Frank D; Lim MS; Fajgenbaum DC
    Hematol Oncol; 2022 Apr; 40(2):191-201. PubMed ID: 35104370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
    Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
    J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Uldrick TS; Bagg A; Frank D; Wu D; Srkalovic G; Simpson D; Liu AY; Menke D; Chandrakasan S; Lechowicz MJ; Wong RS; Pierson S; Paessler M; Rossi JF; Ide M; Ruth J; Croglio M; Suarez A; Krymskaya V; Chadburn A; Colleoni G; Nasta S; Jayanthan R; Nabel CS; Casper C; Dispenzieri A; Fosså A; Kelleher D; Kurzrock R; Voorhees P; Dogan A; Yoshizaki K; van Rhee F; Oksenhendler E; Jaffe ES; Elenitoba-Johnson KS; Lim MS
    Blood; 2017 Mar; 129(12):1646-1657. PubMed ID: 28087540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?
    Nishimura Y; Nishikori A; Sawada H; Czech T; Otsuka Y; Nishimura MF; Mizuno H; Sawa N; Momose S; Ohsawa K; Otsuka F; Sato Y
    J Clin Exp Hematop; 2022 Jun; 62(2):99-105. PubMed ID: 35249898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous and systemic plasmacytosis vs. cutaneous plasmacytic castleman disease: review and speculations about pathogenesis.
    Haque M; Hou JS; Hisamichi K; Tamada K; Cusack CA; Abdelmalek M; Brown RE; Vonderheid EC
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):453-61. PubMed ID: 21940235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEXAS syndrome: A new mimicker of idiopathic multicentric Castleman disease.
    Philip R; Cadro V; Aouba A; Chantepie S; Bracquemart C; Dumont A
    Joint Bone Spine; 2024 Jul; 91(4):105731. PubMed ID: 38583690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology.
    Soudet S; Fajgenbaum D; Delattre C; Forestier A; Hachulla E; Hatron PY; Launay D; Terriou L
    Curr Res Transl Med; 2018 Sep; 66(3):83-86. PubMed ID: 30108026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous involvement as initial presentation of multicentric plasmacytic Castleman disease.
    Chen H; Ba W; Chen H; Yang H
    J Cutan Pathol; 2021 May; 48(5):701-705. PubMed ID: 33469928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
    van Rhee F; Voorhees P; Dispenzieri A; Fosså A; Srkalovic G; Ide M; Munshi N; Schey S; Streetly M; Pierson SK; Partridge HL; Mukherjee S; Shilling D; Stone K; Greenway A; Ruth J; Lechowicz MJ; Chandrakasan S; Jayanthan R; Jaffe ES; Leitch H; Pemmaraju N; Chadburn A; Lim MS; Elenitoba-Johnson KS; Krymskaya V; Goodman A; Hoffmann C; Zinzani PL; Ferrero S; Terriou L; Sato Y; Simpson D; Wong R; Rossi JF; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Oksenhendler E; Fajgenbaum DC
    Blood; 2018 Nov; 132(20):2115-2124. PubMed ID: 30181172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatoid arthritis-like active synovitis with T-cell activation in a case of idiopathic multicentric Castleman disease: A case report.
    Otsuka M; Koga T; Sumiyoshi R; Okamoto M; Endo Y; Tsuji S; Takatani A; Shimizu T; Igawa T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Daisuke N; Kawakami A
    Medicine (Baltimore); 2019 May; 98(18):e15237. PubMed ID: 31045763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Futatsuya C; Mizutani KI; Kumagai M; Shioya A; Guo X; Aikawa A; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Yamada S
    Hum Pathol; 2018 Jul; 77():130-138. PubMed ID: 29684500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicentric Castleman disease with cutaneous manifestations: report of 2 cases and comparison with systemic plasmacytosis.
    Higashi Y; Kanekura T; Sakamoto R; Mochitomi Y; Kanzaki T
    Dermatology; 2007; 214(2):170-3. PubMed ID: 17341868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab.
    Furutera N; Fukunaga N; Okita J; Suzuki T; Suenaga Y; Oyama Y; Aoki K; Fukuda A; Nakata T; Uesugi N; Daa T; Hisano S; Shibata H
    CEN Case Rep; 2021 Feb; 10(1):35-41. PubMed ID: 32715375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.